Can-Fite BioPharma Files 6-K, Incorporates Press Release
Ticker: CANF · Form: 6-K · Filed: Dec 29, 2025 · CIK: 1536196
| Field | Detail |
|---|---|
| Company | Can-Fite Biopharma LTD. (CANF) |
| Form Type | 6-K |
| Filed Date | Dec 29, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing-update, press-release, registration-statement
Related Tickers: CANF
TL;DR
Can-Fite BioPharma filed a 6-K on 12/29, incorporating a 12/26 press release into its S-8 and F-3 filings.
AI Summary
Can-Fite BioPharma Ltd. filed a Form 6-K on December 29, 2025, to report a press release issued on December 26, 2025. This filing incorporates the press release into existing registration statements on Form S-8 and Form F-3.
Why It Matters
This filing serves to officially incorporate a recent press release into Can-Fite's SEC filings, making its contents part of the company's public record for investors and regulators.
Risk Assessment
Risk Level: low — This is a routine filing to incorporate a press release, not indicating new material events or financial distress.
Key Players & Entities
- Can-Fite BioPharma Ltd. (company) — Filer of the 6-K
- December 29, 2025 (date) — Filing date of the 6-K
- December 26, 2025 (date) — Date press release was issued
- Form S-8 (document) — Registration statement incorporated by reference
- Form F-3 (document) — Registration statement incorporated by reference
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K is to report a press release issued by Can-Fite BioPharma Ltd. on December 26, 2025, and to incorporate it by reference into the company's existing Registration Statements on Form S-8 and Form F-3.
When was the press release mentioned in the filing issued?
The press release was issued on December 26, 2025.
What are the file numbers for the Registration Statements being updated?
The Form S-8 Registration Statements are File Nos. 333-227753, 333-271384, and 333-278525. The Form F-3 Registration Statements are File Nos. 333-236064, 333-274316, 333-262055, 333-276000, and 333-281872.
What is the principal executive office address for Can-Fite BioPharma Ltd.?
The principal executive offices are located at 26 Ben Gurion Street, Ramat Gan 5257346, Israel.
Under which SEC Act is this report filed?
This report is filed under the Securities Exchange Act of 1934.
Filing Stats: 259 words · 1 min read · ~1 pages · Grade level 10.2 · Accepted 2025-12-29 06:03:50
Filing Documents
- ea0271068-6k_canfite.htm (6-K) — 11KB
- ea027106801ex99-1_canfite.htm (EX-99.1) — 12KB
- 0001213900-25-125575.txt ( ) — 24KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: December 29, 2025 By: /s/ Motti Farbstein Motti Farbstein Chief Executive Officer and Chief Financial Officer 3